Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05818553 · ClinicalTrials.gov registry record · Phase 2

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

A Phase 2 study of SCN2A Encephalopathy and SCN8A Encephalopathy, sponsored by Praxis Precision Medicines.

Active
Registry status
Phase 2
Development phase
77
Enrollment target
8
Study locations

NCT05818553 is a Phase 2 study of SCN2A Encephalopathy and SCN8A Encephalopathy that is active but no longer recruiting, run by Praxis Precision Medicines. The registered enrollment target is 77 participants. The trial reports 8 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05818553, a Phase 2 study of SCN2A Encephalopathy and SCN8A Encephalopathy, is active but no longer recruiting, sponsored by Praxis Precision Medicines.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
77 participants
Enrollment target
8
Study locations

Study Summary

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

Interventions

  • DRUG PRAX-562

Study Locations (8)

Other

  • Praxis Research Site - Tel Litwinsky
  • Praxis Research Site - Madrid
  • Praxis Research Site - Glasgow
  • Praxis Research Site - London

Georgia

  • Praxis Research Site - Atlanta

Illinois

  • Praxis Research Site - Chicago

Minnesota

  • Praxis Research Site - Minneapolis

New Jersey

  • Praxis Research Site - Hackensack

Trial Details

FieldValue
Enrollment Target 77 participants
Start Date 2023-08-02
Est. Completion 2027-03-01
Phase Phase 2

Sponsor

Praxis Precision Medicines

13 total trials

What the Registry Record Tells You About NCT05818553

The ClinicalTrials.gov registry entry for NCT05818553 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Praxis Precision Medicines, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with SCN2A Encephalopathy appearing as the primary indexed condition, and to 1 intervention - of which PRAX-562 is the first listed.

NCT05818553 reports 8 study locations spanning 5 distinct geographic areas - top geographies include Other, Georgia, Illinois.

Frequently Asked Questions

What is clinical trial NCT05818553 about?

NCT05818553 is a clinical study titled "A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)". A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

What is the current status of trial NCT05818553?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2023-08-02. Estimated completion is 2027-03-01.

What conditions does trial NCT05818553 study?

This clinical trial studies the following conditions: SCN2A Encephalopathy, SCN8A Encephalopathy.

What interventions are being tested in trial NCT05818553?

The interventions under investigation include: PRAX-562 (DRUG).

Who is sponsoring clinical trial NCT05818553?

This trial is sponsored by Praxis Precision Medicines, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05818553 being conducted?

This trial has 8 study locations across Georgia, Illinois, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for SCN2A Encephalopathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.